Received Jun 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA)) | MODERNA | 2 | B0005 | IM / LA |
Patient received Moderna, dose #1 on 4/16/2025. She came to the office on 5/28/2025 for dose #2 of the primary series. Interim Considerations/CDC.gov, were reviewed prior to administration. Upon review, it was noted that an unvaccinated person would receive 2 doses, separated by 4 to 8 weeks. Dose #2 of Moderna was administered, 6 weeks after dose #1. Upon entering the vaccination dose into vaccination database, it was noted the dose was possibly administered too early. Upon further review of the CDC Interim Considerations, the 6 months to 4-year-old schedule was used as a reference, not the age 12 to 64 schedule. Ages 12 to 64, only require 1 dose for an unvaccinated person. Patient was notified of the error on 5/28/2025. On 5/29/2025 patient noted to have expected side effects of fever, body aches and sore arm, similar to dose #1. These symptoms resolved within 3 days. No additional reports of adverse signs and symptoms.
none
none
none
No allergy to vaccination ingredients.
none